Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy.
暂无分享,去创建一个
Philip Hahnfeldt | Heiko Enderling | Lynn Hlatky | P. Hahnfeldt | L. Hlatky | H. Enderling | N. Almog | Nava Almog
[1] B. Thiers,et al. Identification of cells initiating human melanomas , 2009 .
[2] A. Harris,et al. Notch3 signalling promotes tumour growth in colorectal cancer , 2011, The Journal of pathology.
[3] P. Bragado,et al. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. , 2009, Cancer research.
[4] P Hahnfeldt,et al. Migration rules: tumours are conglomerates of self-metastases , 2009, British Journal of Cancer.
[5] Lynn Hlatky,et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] J. Aguirre-Ghiso,et al. Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.
[7] D. Felsher. Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. , 2008, Lymphatic research and biology.
[8] F. Hodi,et al. Tumor and Stem Cell Biology Cancer Research Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells , 2010 .
[9] I. Screpanti,et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. , 2009, Cancer research.
[10] S. Indraccolo,et al. Ligand-driven activation of the Notch pathway in T-all and solid tumors: Why Not(ch)? , 2010, Cell cycle.
[11] B. Quesnel,et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors , 2010, Cancer Immunology, Immunotherapy.
[12] P. Goss,et al. Does tumour dormancy offer a therapeutic target? , 2010, Nature Reviews Cancer.
[13] D. Felsher. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. , 2010, Genes & cancer.
[14] K. Basso,et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. , 2011, Blood.
[15] Raghu Kalluri,et al. Cancer without disease , 2004, Nature.
[16] Jonathan W. Uhr,et al. Controversies in clinical cancer dormancy , 2011, Proceedings of the National Academy of Sciences.
[17] P. Hahnfeldt,et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.
[18] William C Hines,et al. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.
[19] R. Raychowdhury,et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. , 2009, Cancer research.
[20] G. Basso,et al. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells , 2011, Leukemia.
[21] David Zurakowski,et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.
[22] M. Chaplain,et al. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. , 2009, Cancer research.
[23] B. Quesnel,et al. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. , 2004, Blood.
[24] N. Almog. Molecular mechanisms underlying tumor dormancy. , 2010, Cancer letters.
[25] P. Bragado,et al. ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease , 2011, Clinical Cancer Research.